Short Interest in Profusa, Inc. (NASDAQ:PFSA) Decreases By 59.6%

Profusa, Inc. (NASDAQ:PFSA) saw a significant decrease in short interest in May. As of May 15th, there was short interest totaling 268,839 shares, a decrease of 59.6% from the April 30th total of 665,135 shares. Based on an average trading volume of 243,966 shares, the days-to-cover ratio is presently 1.1 days. Approximately 6.5% of the company’s shares are short sold.

Profusa Price Performance

Profusa stock opened at $0.34 on Tuesday. Profusa has a 52 week low of $0.33 and a 52 week high of $180.00. The firm has a market cap of $1.60 million, a PE ratio of 0.00 and a beta of 0.35. The stock’s fifty day simple moving average is $0.59.

Profusa (NASDAQ:PFSA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($2.05) EPS for the quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research note on Friday, March 27th. Wall Street Zen raised Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Profusa has a consensus rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.